Changes in Hong Kong stocks | Hengrui Pharmaceutical (01276) rose more than 5% in the afternoon. The company officially launched a new round of repurchases and spent 14.5 million yuan in the first repurchase

The Zhitong Finance App learned that Hengrui Pharmaceutical (01276) rose more than 5% in the afternoon. As of press release, it rose 5.22% to HK$46.74, with a turnover of HK$171 million.

According to the news, on the evening of September 17, Hengrui Pharmaceutical issued an announcement stating that the company repurchased 335,000 A-shares for the first time through centralized bidding transactions, accounting for 0.005% of the company's total share capital, and has paid a total amount of 14.5036 million yuan. According to the announcement issued earlier, the company's total repurchase capital is not less than RMB 1 billion and not more than RMB 2 billion. Just before this new round of buybacks began, Hengrui Pharmaceutical had just completed the previous round of share repurchases.

Notably, on September 15, Hengrui Pharmaceutical announced that its subsidiary Fujian Shengdi Pharmaceutical's HRS-4139 tablets were approved for clinical trials by the State Drug Administration and agreed to conduct clinical trials for moderate to severe plaque psoriasis. On the same day, the subsidiary Guangdong Hengrui Pharmaceutical received clinical trial approval and agreed to conduct a phase III clinical trial. The indication is for use in adult patients with intracranial atherosclerotic stenosis to reduce the risk of recurrence of stroke.